Contrasting Boston Scientific (NYSE:BSX) & Invivo Therapeutics (NVIV)

Invivo Therapeutics (NASDAQ: NVIV) and Boston Scientific (NYSE:BSX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Insider & Institutional Ownership

11.9% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 89.8% of Boston Scientific shares are owned by institutional investors. 3.9% of Invivo Therapeutics shares are owned by insiders. Comparatively, 0.7% of Boston Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Invivo Therapeutics and Boston Scientific’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Invivo Therapeutics N/A -134.23% -109.16%
Boston Scientific 1.15% 24.04% 9.57%

Earnings & Valuation

This table compares Invivo Therapeutics and Boston Scientific’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invivo Therapeutics N/A N/A -$23.43 million ($0.85) -0.61
Boston Scientific $9.05 billion 4.13 $105.00 million $0.07 388.57

Boston Scientific has higher revenue and earnings than Invivo Therapeutics. Invivo Therapeutics is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Invivo Therapeutics and Boston Scientific, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invivo Therapeutics 0 1 0 0 2.00
Boston Scientific 0 4 12 1 2.82

Invivo Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 1,053.85%. Boston Scientific has a consensus target price of $30.87, suggesting a potential upside of 13.48%. Given Invivo Therapeutics’ higher probable upside, equities research analysts clearly believe Invivo Therapeutics is more favorable than Boston Scientific.

Volatility and Risk

Invivo Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Summary

Boston Scientific beats Invivo Therapeutics on 10 of the 13 factors compared between the two stocks.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply